Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Patients With Previously Treated Metastatic, Microsatellite-Stable Colorectal Adenocarcinoma With High CEACAM5 Expression

NCT03866239 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03866239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03866239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Patients With Previously Treated Metastatic, Microsatellite-Stable Colorectal Adenocarcinoma With High CEACAM5 Expression
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Terminated
Start date
May 7, 2019
Completion date
March 13, 2024
Enrollment
47 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer